Telomere shortening is associated with increased risk of disease and decreased lifespan. Various nutrients have been shown to support the length and health of telomeres in clinical and preclinical studies.
Scientifically reviewed by: Gary Gonzalez, MD, in May 2026. Written by: Richard Ross.
In 2015, Liz Parrish flew to Colombia and let someone inject an untested gene therapy into her body 150 times. She texted her kids that she loved them before it started. When it was over, she went for nachos.
Ten years later, her telomeres are longer than when she started, and she has taken 12 gene therapies in total.
Her decade of self-experimentation has produced peer-reviewed data, a growing protocol of gene therapies, and a company training its sights on making biological aging optional. Our conversation goes over what it took to become patient zero and what gene therapy for aging looks like in practice today, among other things.
As freshwater shortages intensify around the world, scientists are searching for technologies that can do more than simply desalinate seawater. One of the biggest challenges is treating oil-contaminated seawater, where conventional desalination systems often fail because oil clogs membranes, blocks water transport and reduces efficiency.
SAN FRANCISCO – Rubicon Space Systems completed hot-fire testing of its Velox 5-newton ASCENT monopropellant thruster, paving the way for on-orbit operations in 2027.
“The program demonstrated performance beyond our design objectives,” Rubicon Director Daniel Cavender told SpaceNews. “We are now transitioning the thruster into flight production.”
The Velox thruster, fueled with ASCENT, a hydrazine replacement, was tested in Rubicon’s vacuum altitude test chamber in Huntsville, Alabama.
When people work in pairs or teams, they can often solve a wider range of problems, completing some tasks faster and more efficiently than they would alone. To assist users similarly to how other humans would, robots should be able to rapidly interpret human behaviors and commands, using their predictions to plan and precisely execute helpful actions.
Researchers at GenerativeBionics, Italian Institute of Technology (IIT) and University of Manchester recently introduced a framework that could guide the design of robots that interact with humans more safely, efficiently and adaptively. Their design strategy, introduced in a paper published in Nature Machine Intelligence, was already used to create a new humanoid robot called ergoCub.
“Our work grew out of many years of experience developing different generations of humanoid robots,” Carlotta Sartore and Daniele Pucci, the paper’s first and senior authors, respectively, told Tech Xplore. “During this time, we repeatedly observed that robot hardware was often treated as fixed, while the control system was expected to compensate for its physical limitations.
Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body’s immune response, a discovery that could help scientists develop new treatments that make cancer immunotherapies more effective.
Published in the Journal of Clinical Investigation, the study identifies a previously unknown role for a protein called TRAILshort, which acts like an immune “off switch.” The researchers found that TRAILshort prevents T cells — the immune system’s primary cancer-fighting cells — from recognizing and destroying cancer and virus-infected cells. In preclinical models, blocking the protein restored T-cell activity and improved immune response.
The researchers also found that TRAILshort reduces the effectiveness of chimeric antigen receptor-T cell therapy (CAR-T cell therapy), one of the most advanced forms of cancer immunotherapy. Their findings suggest that therapies designed to block TRAILshort could improve CAR-T treatment and potentially benefit other immune-based cancer therapies.
